Interested in Urology Cancers, biomarkers and drug development.
- Tweets 2,666
- Following 88
- Followers 14,076
- Likes 683
Tom Powles retweeted
48 concomitant publications at #ESMO26 enabling research from the congress to peer-reviewed journals
A huge effort behind the scenes from authors, reviewers and editorial teams 👏🏻
@myESMO @OncoAlert @Annals_Oncology @ESMO_Open @NEJM @NatureMedicine @TheLancet @JAMA_current
Concomitant publications at #ESMO26: new data moving swiftly from the podium to the peer-reviewed journals.
@Annals_Oncology @ESMO_Open @NEJM @NatureMedicine @TheLancet @TheLancetOncol @Nature @JAMA_current
1
5
21
1,251
Tom Powles retweeted
Thank you, Prof. Cavalli and @tompowles1 for your vision, dedication, and leadership.
Proud to be part of the Annals of Oncology family and its remarkable journey.
@myESMO @OncoAlert @curijoey #ESMO26
Annals of Oncology - past and present: Editor-in-Chief @tompowles1 talks to the journal's founding Editor, Prof. Franco Cavalli, during the #ESMO2026 Congress
7
14
651
Tom Powles retweeted
Annals of Oncology - past and present: Editor-in-Chief @tompowles1 talks to the journal's founding Editor, Prof. Franco Cavalli, during the #ESMO2026 Congress
3
18
2,259
Tom Powles retweeted
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
15
88
236
25,521
Tom Powles retweeted
Thank you Colleagues for a phenomenal #ESMO26
ESMO in Madrid is a wrap, and we are grateful to everyone who shared, discussed, debated and amplified the science this week. You turned five days in Madrid into a truly global conversation. 🌍 OUR Network's MISSION: Keep our colleagues worldwide Up To date in REAL TIME.
📣 101.7M impressions of potential reach
💬 6.1K posts on X from 988 participants in 34 countries
⚡ 43.1 posts per hour across the meeting days
😊 45% positive sentiment, with only 6% negative
Real-time metrics powered by ACUVOX. WWW.ACUVOX.IO
🏆 Top influencers
@DrChoueiri, @StephenVLiu, @PTarantinoMD, @dr_yakupergun, @HHorinouchi, @zklaassen_md, @stolaney1, @ArndtVogel, @DrYukselUrun, @DraMartinezLago, @tompowles1, @SuyogCancer, @adamfeuerstein, @ScaltritiLab, @GIMedOnc, @ScottGottliebMD, @barriere_dr, @_ShankarSiva, @miriamgonp, @TiansterZhang, @matteolambe, @NiuSanford, @christine_lovly, @amerseburger, @GlopesMd, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @Lucarecco, @mzugman, @p_ciracimd, @DrVilmaPBarcia, @MarioBalsaMD, @scocmem, @GaiaGriguolo, @JankovicK, @Dr_Oncologista
🌎 Where the conversation came from
North America led with 1,940 posts, followed closely by Europe with 1,777. Boston, Madrid and New York were the most active cities.
🔬 Top studies by impact
1️⃣ DeLLphi-305 (SCLC): 4.0M reach, 170 posts
2️⃣ VOLGA (bladder): 3.7M reach, 141 posts
3️⃣ KRASCENDO-1 (NSCLC): 3.5M reach
4️⃣ SAFFRON (NSCLC): 3.3M reach
5️⃣ INTerpath-001 (melanoma): 154 posts
Pinging our Collaborators
17
46
9,564
Tom Powles retweeted
If/when VOLGA regimen is approved, is this something (3 cycles of EV-Durva) you’d extrapolate for cis eligible MIBC patients as well and use this approach broadly or stick with EV-Pembro (EV304: and push for 9 cycles of EV)? @PGrivasMDPhD @shilpaonc @drenriquegrande @DrKarineTawagi @UroDocAsh @bergsa83 @MikeSerzanMD @BrendanGuercio #ESMO26 @tompowles1 @dr_yakupergun @DrYukselUrun
5
19
42
5,516
I think you would be great at it Monty. Definitely got my vote. @DrChoueiri @OncoAlert @neerajaiims @brian_rini @Uromigos @LosUromigos @uromigosjapan
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
2
14
52
2,544
Tom Powles retweeted
🚨 One of the most attractive aspects of VOLGA: EV only neoadjuvantly! 100% agree with you Tom @tompowles1
Just 3 cycles of EV + perioperative durvalumab delivered impressive efficacy in cisplatin-ineligible MIBC:
🔹 EFS HR 0.51
🔹 OS HR 0.58
🔹 pCR 45% vs 10%
No adjuvant EV required by the regimen.
This is particularly relevant because cumulative EV exposure matters: peripheral neuropathy often emerges later during treatment. Incidence 36% in 905/B15 compared to only 18% in VOLGA!
Could avoiding adjuvant EV reduce long-term toxicity, treatment burden and financial toxicity while maintaining excellent outcomes?
Importantly, VOLGA cannot tell us whether omitting adjuvant EV is equally effective as the longer EV regimens used in KEYNOTE-905/B15. Cross-trial toxicity comparisons are also confounded by different populations and reporting.
The next step should be response-adapted perioperative treatment, potentially integrating pCR and ctDNA clearance to identify who truly needs postoperative intensification.
Maximize cure. Minimize unnecessary treatment. 👏 #ESMO26 #BladderCancer
@OncoAlert @weoncologists @urotoday @Uromigos
@OncoAlert and Faculty: @DrChoueiri @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
Why ‘More Drugs’ Isn’t Always Better: VOLGA Trial Redefines #BladderCancer Care
#Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial @jteoh_hk @CPRT65
🔬 Phase 3 VOLGA trial (n=695)
Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC).
Just PUBLISHED in @NEJM
nejm.org/doi/full/10.1056/NE…
Interim analysis; median event-free survival (EFS) follow-up: 22.9 months.
➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83)
➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance
➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control
➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control
✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS.
🎙️ Presenter: Thomas Powles
👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto
@DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @niklas_kluemper @Markuseckstein3
10
28
2,066
Similar response rates. Different trial outcomes. 🎙️
In Episode 521, Rob Jones joins the Uromigos to unpack differing chemotherapy–immunotherapy trial results in muscle invasive bladder cancer, what pathologic complete response really tells us, and how patient selection may shape outcomes.
Swipe for the highlights, then tune in for the full discussion: bit.ly/4eZI6ts
#Uromigos #ESMO26
1
4
6
626
Tom Powles retweeted
Absolutely no surprise here! 🎉👏 So well deserved @brian_rini & @tompowles1
A huge fan of @Uromigos and the brilliant Tom and Brian❤️ Their passion, wit, and ability to bring the global GU oncology community together for insightful, engaging, and entertaining conversations make this podcast truly special and unique with a 🌏 footprint!
Congratulations on this wonderful recognition! 🎙️🏆
@LosUromigos @uromigosjapan @OncoAlert @montypal @neerajaiims @Silke_Gillessen @PGrivasMDPhD @DrChoueiri @ChrisSweens1 @kalasri3
@myESMO @UroDocAsh
A little something to celebrate! 🎙️
The Uromigos podcast has been recognized by @_feedspot as one of the Top 100 Oncology Podcasts!
A BIG thank you to our incredible guests, listeners, and the global oncology community for being part of the conversation.
🎧 Join the conversation wherever you listen to podcasts!
4
11
40
2,529
Tom Powles retweeted
Dear colleagues,
We are already curating THE COMPLETE #ESMO26 NEWSLETTER 📰 our picks of the top trials presented in Madrid, together in one email.
Register to receive it 👉 buff.ly/N5gYtAc
Every newsletter is curated by oncologists, for colleagues working in cancer care. It’s our way of making science quick and accessible.
We are OncoAlert🚨 For Colleagues, by Colleagues
Best,
The Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
2
26
44
9,912
Amazing APCCC prostate consensus statement out today on early prostate cancer. Experts from around the world come together in Lugano to address the most contravercial issues. @Silke_Gillessen @neerajaiims @DrChoueiri @OncoAlert kwnsfk27.r.eu-west-1.awstrac…
3
33
108
7,866
Tom Powles retweeted
Such an impt trial and lots to learn from it. Agree completely w your conclusions.
4
3
1,029
Triplets in 1st line RCC failed in LS12 @Annals_Oncology @brian_rini (n=1500!). There are not many combinations with HIF/VEGF/PD1 left to test and this approach has probably run its course. It’s time for a new chapter in RCC with T cell engagers and bispecifics #ESMO26 @montypal @DrChoueiri @OncoAlert
4
15
41
2,243
Biomarker analysis exploring within-patient gene-expression ratios and deterministic single-sample predictions. This is an alternative to the high vs low classic approach @brian_rini #ESMO26
Several groups have attempted to predict the IM151 RCC clusters with flawed methods. We developed IRIS-RCC (Individual RNA-seq Intrinsic Subtyping for RCC; available at irisrcc.vindhyadatascience.c…), to predict clusters using an individual-sample model.
nature.com/articles/s41698-0…
ALT Development and validation of IRIS-RCC for predicting molecular subgroups in RCC A. Conceptual figure showing the modeling used to derive the IRIS-RCC predictor B. Cross-validation accuracy metrics for the IRIS-RCC predictor, showing boxplots for overall accuracy and sensitivity, positive predictive value, hazard ratio, and odds ratio for each of the cluster groups. C. Prevalence of the different clusters in the training data (IM151), and validation sets (JR101) using two different methods (Saliby and IRIS-RCC). D. Violin and boxplots showing the enrichment of PD-L1+ IHC levels as a fraction of the total immune cells in Cluster IO compared to Cluster Exclude and Cluster Angio E. Violin and boxplots showing the enrichment of CD8+ IHC levels in Cluster IO compared to Cluster Exclude and Cluster Angio F. Heatmap showing mutational associations with clusters
9
21
1,758
Tom Powles retweeted
Dear #ESMO26 Colleagues
The amazing Brian Rini & Tom Powles of @Uromigos give us a preview of everything coming to 🎸 Nashville 🇺🇸 on November 13–14, 2026, for #UromigosLIVE — plus more details about the World Cup happening in November! 🏆
👉 buff.ly/2ovzqHd
@Uromigos @tompowles1 @lalaniMD @AmandaNizamMD @scocmem @DrKarineTawagi @nataliagandur @ReneeSaliby @NazliDizman @uromigosjapan @TresUramigas @weoncologists @APCCC_Lugano
OncoAlert GU Faculty:
@crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @BraunMDPhD @cdanicas @AOmlin
1
4
11
1,724
The MOIO randomised phase 3 non-inferiority trial (n=340) explored early discontinuation of ICI therapy be SOC in advanced patients responding to therapy. It had many flaws (mixed tumors and treatments, small size, early discontinuation etc). Also, due to the statistics, it’s not possible to say whether non-inferiority was achieved (OS HR 1.89 [95%Cl: 1.03,3.48]). Despite these problems it highlights a concern around early discontinuation, which should be taken seriously. Tumour specific trials are needed, but I’m not sure it will be easy to randomize patients . #ESMO26 @OncoAlert @myESMO @Annals_Oncology
3
25
45
2,852
Tom Powles retweeted
A pleasure to catch up with so many terrific people at #ESMO26! @tompowles1, @DrChoueiri, @FedefedeFri, @alshamsi2000, @DrYukselUrun, @ProfSyedHussain, @ErikaHamilton9, @jrgralow, @MatteoSantoniMD, @chadinabhan, @OncHahn, @TiansterZhang, @AnaVManana - and that's just skimming the surface! #Oncology truly takes a village & this meeting has brought so many drivers of progress under one roof!
7
13
97
4,917
Phase 1b combination data for elfetabart drozuntecan (B7H3/Topo-1 ADC) combined with pumitamig (VEGF/PD1 bispecific) shows striking response relates with ~40% G3/4 AEs. Perhaps the best new combination data #ESMO26 . EV + VEGF/PD1 combos are under investigation in bladder cancer too with EV. @OncoAlert
2
25
61
3,820